Regeneron (REGN) Reports Positive 2-Yr Results from Phase 3 PANORAMA Trial Evaluating EYLEA (aflibercept) Injection 2mg
Go back to Regeneron (REGN) Reports Positive 2-Yr Results from Phase 3 PANORAMA Trial Evaluating EYLEA (aflibercept) Injection 2mg| Regeneron (NASDAQ: REGN) | Delayed: 612.50 +2.56 (0.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $609.94 | 52 Week High | $592.36 | |||
| Open | $604.46 | 52 Week Low | $325.35 | |||
| Day High | $613.56 | P/E | 160.76 | |||
| Day Low | $594.90 | EPS | $3.81 | |||
| Volume | 1,604,280 | |||||

